Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical Limited announced the presentation of data from four studies on their respiratory drugs at the 2025 European Respiratory Society Annual Meeting. The studies include TQC3721, a PDE3/4 inhibitor with bronchodilatory and anti-inflammatory effects, which has been granted Breakthrough Therapy Designation in China and is in Phase III trials. TQC2731, a TSLP monoclonal antibody, is progressing rapidly in trials for asthma and other inflammatory diseases. TQC3403, a combination of umeclidinium bromide and vilanterol, is set to become the first marketed generic version in China, expected by 2026. These developments highlight Sino Biopharmaceutical’s strong positioning in the respiratory drug market and potential impact on stakeholders.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development and production of innovative medicines. The company is known for its work in respiratory and autoimmune diseases, with a market focus on China.
YTD Price Performance: 157.24%
Average Trading Volume: 184,018,982
Technical Sentiment Signal: Buy
Current Market Cap: HK$146.1B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.